Identifying determinants of treatment failure with intralesional meglumine antimoniate in patients with cutaneous leishmaniasis
- 10 March 2026
- journal article
- research article
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 122
Abstract
No abstract availableKeywords
Funding Information
- Mashhad University of Medical Sciences (970611)
This publication has 33 references indexed in Scilit:
- Ecological Niche Modeling of main reservoir hosts of zoonotic cutaneous leishmaniasis in IranActa Tropica, 2016
- Cutaneous Leishmaniasis: Recent Developments in Diagnosis and ManagementAmerican Journal of Clinical Dermatology, 2015
- Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central IranJournal of Infection and Public Health, 2013
- Cutaneous leishmaniasis in Texas: A northern spread of endemic areasJournal of the American Academy of Dermatology, 2008
- Differences in transmission seasons as an epidemiological tool for characterization of anthroponotic and zoonotic cutaneous leishmaniasis in northern AfghanistanActa Tropica, 2008
- Cutaneous leishmaniasisThe Lancet Infectious Diseases, 2007
- Treatment of acute Old World cutaneous leishmaniasis: A systematic review of the randomized controlled trialsJournal of the American Academy of Dermatology, 2007
- Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniateClinical and Experimental Dermatology, 2003
- Gene Amplification in Amphotericin B-Resistant Leishmania tarentolaeExperimental Parasitology, 2001
- Pentostam® (sodium stibogluconate); a 50-year personal reminiscenceTransactions of the Royal Society of Tropical Medicine and Hygiene, 1995